top of page

Merck’s Keytruda meets primary endpoint in urothelial cancer study

A phase 3 study evaluating the use of Merck’s Keytruda (pembrolizumab) immunotherapy in patients with previously treated advanced urothelial cancer, met the primary endpoint of overall survival (OS).




Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page